LERSIVIRINE

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H18N4O2
Molecular Weight	310.3504
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of LERSIVIRINE

Structure Search

SMILES

CCC1=NN(CCO)C(CC)=C1OC2=CC(=CC(=C2)C#N)C#N

InChI

InChIKey=MCPUZZJBAHRIPO-UHFFFAOYSA-N

InChI=1S/C17H18N4O2/c1-3-15-17(16(4-2)21(20-15)5-6-22)23-14-8-12(10-18)7-13(9-14)11-19/h7-9,22H,3-6H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C17H18N4O2
Molecular Weight	310.3504
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:22:39 UTC 2023` Edited by `admin` on `Sat Dec 16 17:22:39 UTC 2023`
Record UNII	R3ZGC15A9A
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LERSIVIRINE

Official Name

English

lersivirine [INN]

Common Name

English

UK-453061

Code

English

UK-453,061

Code

English

LERSIVIRINE [USAN]

Common Name

English

Lersivirine [WHO-DD]

Common Name

English

5-{[3,5-Diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile

Systematic Name

English

1,3-BENZENEDICARBONITRILE, 5-((3,5-DIETHYL-1-(2-HYDROXYETHYL)-1H-PYRAZOL-4-YL)OXY)-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C97453

Created by admin on Sat Dec 16 17:22:41 UTC 2023 , Edited by admin on Sat Dec 16 17:22:41 UTC 2023

Code System Code Type Description

CAS

473921-12-9

Created by admin on Sat Dec 16 17:22:41 UTC 2023 , Edited by admin on Sat Dec 16 17:22:41 UTC 2023

PRIMARY

INN

9147

Created by admin on Sat Dec 16 17:22:41 UTC 2023 , Edited by admin on Sat Dec 16 17:22:41 UTC 2023

PRIMARY

SMS_ID

300000034296

Created by admin on Sat Dec 16 17:22:41 UTC 2023 , Edited by admin on Sat Dec 16 17:22:41 UTC 2023

PRIMARY

DRUG BANK

DB11649

Created by admin on Sat Dec 16 17:22:41 UTC 2023 , Edited by admin on Sat Dec 16 17:22:41 UTC 2023

PRIMARY

NCI_THESAURUS

C83872

Created by admin on Sat Dec 16 17:22:41 UTC 2023 , Edited by admin on Sat Dec 16 17:22:41 UTC 2023

PRIMARY

ChEMBL

CHEMBL571987

Created by admin on Sat Dec 16 17:22:41 UTC 2023 , Edited by admin on Sat Dec 16 17:22:41 UTC 2023

PRIMARY

USAN

UU-162

Created by admin on Sat Dec 16 17:22:41 UTC 2023 , Edited by admin on Sat Dec 16 17:22:41 UTC 2023

PRIMARY

EPA CompTox

DTXSID0057881

Created by admin on Sat Dec 16 17:22:41 UTC 2023 , Edited by admin on Sat Dec 16 17:22:41 UTC 2023

PRIMARY

FDA UNII

R3ZGC15A9A

Created by admin on Sat Dec 16 17:22:41 UTC 2023 , Edited by admin on Sat Dec 16 17:22:41 UTC 2023

PRIMARY

PUBCHEM

16739244

Created by admin on Sat Dec 16 17:22:41 UTC 2023 , Edited by admin on Sat Dec 16 17:22:41 UTC 2023

PRIMARY

Related Record Type Details


					0M77ZW789J

URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 2B7

METABOLIC ENZYME -> SUBSTRATE

Interaction Type:

MAJOR


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> SUBSTRATE

Interaction Type:

MAJOR


					859A956UY8

HUMAN IMMUNODEFICIENCY VIRUS TYPE 1

TARGET ORGANISM->INHIBITOR

Amount:

Related Record Type Details


					589NV24LHC

METABOLITE -> PARENT

Qualification:

FECAL

Amount:


					4737AC7HVQ

2-(4-(3,5-DICYANOPHENOXY)-3,5-DIETHYL-PYRAZOL-1-YL)ETHYL HYDROGEN SULFATE

METABOLITE -> PARENT

Qualification:

URINE

Amount:


					ETE5TH3K4R

BENZOIC ACID, 3-CYANO-5-((3,5-DIETHYL-1-(2-HYDROXYETHYL)-1H-PYRAZOL-4-YL)OXY)-

METABOLITE -> PARENT

Qualification:

FECAL

Amount:


					WM5N3R478N

METABOLITE -> PARENT

Qualification:

PLASMA

Amount:


					2FB3ZTE7U2

METABOLITE -> PARENT

Qualification:

PLASMA

Amount:


					HD6MC2YJ9Q

METABOLITE -> PARENT

Qualification:

PLASMA

Amount:


					LB8PZ67QE9

3-CYANO-5-((3,5-DIETHYL-1H-PYRAZOL-4-YL)OXY)BENZOIC ACID

METABOLITE -> PARENT

Qualification:

FECAL

Amount:

Related Record Type Details


					R3ZGC15A9A

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Tmax	PHARMACOKINETIC				SINGLE ORAL ADMINISTRATION

Biological Half-life	PHARMACOKINETIC				SINGLE ORAL ADMINISTRATION